Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.64 |
| ▸ | MEN1 | O00255 | 2/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.59 |
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 2/20 | 0.55 |
| ▸ | GRK2 | P25098 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | USP2 | O75604 | 1/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | PKM | P14618 | 1/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4022887 | 0.84 | KMT2A (0.87) | KMT2AMEN1ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL2474840 | 0.83 | KMT2A (0.74) | KMT2AMEN1ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL3739676 | 0.80 | ACHE (0.56) | KMT2AMEN1ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL4023394 | 0.79 | KMT2A (0.79) | KMT2AMEN1ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL4028185 | 0.78 | KMT2A (0.73) | KMT2AMEN1ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL264967 | 0.78 | MAPT (0.53) | KMT2AMEN1ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL6375210 | 0.78 | KMT2A (0.81) | KMT2AMEN1ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL23392535 | 0.78 | MAPT (0.77) | KMT2AMEN1ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL23417617 | 0.78 | ALDH1A1 (0.77) | KMT2AMEN1ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL21579855 | 0.78 | POLB (0.65) | KMT2AMEN1ALDH1A1MAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1751111-B1 | SUBSTITUTED 1,2,3,4-TETRAHYDROISOQUINOLINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2014-12-31 | — | — | EP | disclosed |
| EP-1751111-B1 | SUBSTITUTED 1,2,3,4-TETRAHYDROISOQUINOLINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2014-12-31 | — | — | EP | disclosed |
| CN-1926109-B | Substituted 1,2,3, 4-tetrahydroisoquinoline derivatives | ACTELION PHARMACEUTICALS LTD | 2011-04-13 | — | — | CN | disclosed |
| US-20100256182-A1 | SUBSTITUTED 1,2,3,4-TETRAHYDROISOQUINOLINE DERIVATIVES | AISSAOUI HAMED | 2010-10-07 | — | — | US | disclosed |
| US-20100256182-A1 | SUBSTITUTED 1,2,3,4-TETRAHYDROISOQUINOLINE DERIVATIVES | AISSAOUI HAMED | 2010-10-07 | — | — | US | disclosed |
| US-20100256182-A1 | SUBSTITUTED 1,2,3,4-TETRAHYDROISOQUINOLINE DERIVATIVES | AISSAOUI HAMED | 2010-10-07 | — | — | US | disclosed |
| US-7763638-B2 | Substituted 1,2,3,4-tetrahydroisoquinoline derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-07-27 | — | — | US | disclosed |
| US-7763638-B2 | Substituted 1,2,3,4-tetrahydroisoquinoline derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-07-27 | — | — | US | disclosed |
| US-7763638-B2 | Substituted 1,2,3,4-tetrahydroisoquinoline derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-07-27 | — | — | US | disclosed |
| US-20070191424-A1 | Substituted 1,2,3,4-tetrahydroisoquinoline derivatives | IDORSIA PHARMACEUTICALS LTD (CH) | 2007-08-16 | — | — | US | disclosed |
| US-20070191424-A1 | Substituted 1,2,3,4-tetrahydroisoquinoline derivatives | IDORSIA PHARMACEUTICALS LTD (CH) | 2007-08-16 | — | — | US | disclosed |
| US-20070191424-A1 | Substituted 1,2,3,4-tetrahydroisoquinoline derivatives | IDORSIA PHARMACEUTICALS LTD (CH) | 2007-08-16 | — | — | US | disclosed |
| CN-1926109-A | Substituted 1,2,3, 4-tetrahydroisoquinoline derivatives | ACTELION PHARMACEUTICALS LTD (CH) | 2007-03-07 | — | — | CN | disclosed |
| EP-1751111-A1 | SUBSTITUTED 1,2,3,4-TETRAHYDROISOQUINOLINE DERIVATIVES | Actelion Pharmaceuticals Ltd. (CH) | 2007-02-14 | — | — | EP | disclosed |
| WO-2005118548-A1 | SUBSTITUTED 1,2,3,4-TETRAHYDROISOQUINOLINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2005-12-15 | — | — | WO | disclosed |
| WO-2005118548-A1 | SUBSTITUTED 1,2,3,4-TETRAHYDROISOQUINOLINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2005-12-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256182-A1 | SUBSTITUTED 1,2,3,4-TETRAHYDROISOQUINOLINE DERIVATIVES | CYP4B1, RECQL, NQO1 | KMT2A 2266/4885MEN1 751/4885ALDH1A1 477/4885 |
| US-20070191424-A1 | Substituted 1,2,3,4-tetrahydroisoquinoline derivatives | CPT1A, NQO1, COQ8A | KMT2A 2028/4885MEN1 2601/4885ALDH1A1 1448/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.